Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer
NCT03834571Phase 2Withdrawn
- Sponsor
- AIDS Malignancy Consortium
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of carboplatin, Paclitaxel Micelles for Injection in Cervical Cancer (CC), sponsored by AIDS Malignancy Consortium. Planned start May 2022; status: withdrawn.
02
Drugs
carboplatinPaclitaxel Micelles for Injection
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03834571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834571.